Vion Suspends Cloretazine Phase III Enrollment In Leukemia Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Suspension is a “hiccup” but development of the alkylating agent for adult myelogenous leukemia will move forward, Vion CEO Kessman states.